Sana Biotechnology, Inc. (SANA) insider details RSU vesting and stock sale

Rhea-AI Filing Summary

Sana Biotechnology, Inc. officer Susan D. Wyrick reported activity in company stock. On December 13, 2025, 3,400 restricted stock units vested and converted into common stock at a price of $0.00 per share, increasing her directly held shares. On December 15, 2025, she disposed of 873 shares at $5.22 per share, after which she held 180,790 shares of common stock directly. The filing notes that the restricted stock unit award vested in full on December 13, 2025 and identifies Wyrick as Acting Chief Financial Officer and Principal Accounting Officer.

Insider Trade Summary

Net Buyer: 2,527 shares

Net Buy 3 txns

Insider Wyrick Susan D.

Role See Remarks

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	873	$5.22	$5K
Exercise	Restricted Stock Units	3,400	$0.00	$0.00
Exercise	Common Stock	3,400	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct); Common Stock — 180,790 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. common stock.
2. F2. The award vested as to 100% of the restricted stock units on December 13, 2025.

FAQ

What insider transaction did Sana Biotechnology (SANA) report in this Form 4?

The filing shows that officer Susan D. Wyrick had 3,400 restricted stock units vest and convert into common stock on December 13, 2025, and she later disposed of 873 shares on December 15, 2025.

How many Sana Biotechnology (SANA) shares does Susan D. Wyrick own after the reported transactions?

After the reported transactions, Susan D. Wyrick beneficially owns 180,790 shares of Sana Biotechnology, Inc. common stock held directly.

What RSU award vested for the Sana Biotechnology (SANA) officer?

An award of 3,400 restricted stock units vested as to 100% of the units on December 13, 2025, with each unit representing a contingent right to receive one share of common stock.

At what prices were the Sana Biotechnology (SANA) share transactions reported?

The RSU conversion on December 13, 2025, was reported at $0.00 per share, and the disposal of 873 shares on December 15, 2025, was reported at $5.22 per share.

What is Susan D. Wyricks role at Sana Biotechnology (SANA)?

The remarks identify Susan D. Wyrick as Sana Biotechnology, Inc.s Acting Chief Financial Officer and Principal Accounting Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 12/16/2025 - 04:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wyrick Susan D.

(Last) (First) (Middle)

C/O SANA BIOTECHNOLOGY, INC.

188 EAST BLAINE STREET, SUITE 400

(Street)

SEATTLE WA 98102

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sana Biotechnology, Inc. [ SANA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
12/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/13/2025		M		3,400	A	$0.00	181,663	D
Common Stock	12/15/2025		F		873	D	$5.22	180,790	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	12/13/2025		M			3,400	(2)	(2)	Common Stock	3,400	(1)	0.00	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. common stock.

2. The award vested as to 100% of the restricted stock units on December 13, 2025.

Remarks:

Acting Chief Financial Officer and Principal Accounting Officer

	/s/ Aaron M. Grossman, Attorney-in-Fact for Susan D. Wyrick	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.